Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Licitra L, et al. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265711 Clinical Trial.
Biological agents in head and neck cancer.
Bossi P, Locati LD, Licitra L. Bossi P, et al. Among authors: licitra l. Expert Rev Anticancer Ther. 2007 Nov;7(11):1643-50. doi: 10.1586/14737140.7.11.1643. Expert Rev Anticancer Ther. 2007. PMID: 18020930 Review.
Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience.
Palazzi M, Orlandi E, Bossi P, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantù G, Licitra L, Olmi P, Tomatis S. Palazzi M, et al. Among authors: licitra l. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):774-80. doi: 10.1016/j.ijrobp.2008.08.068. Epub 2009 Feb 26. Int J Radiat Oncol Biol Phys. 2009. PMID: 19250771
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Stewart JS, et al. Among authors: licitra l. J Clin Oncol. 2009 Apr 10;27(11):1864-71. doi: 10.1200/JCO.2008.17.0530. Epub 2009 Mar 16. J Clin Oncol. 2009. PMID: 19289630 Clinical Trial.
Head and neck cancer.
Psyrri A, Burtness B, Harari PM, Vermorken JB, Licitra L, Sasaki CT. Psyrri A, et al. Among authors: licitra l. J Oncol. 2009;2009:358098. doi: 10.1155/2009/358098. Epub 2010 Feb 4. J Oncol. 2009. PMID: 20169126 Free PMC article. No abstract available.
Multikinase inhibitors in thyroid cancer.
Licitra L, Locati LD, Greco A, Granata R, Bossi P. Licitra L, et al. Eur J Cancer. 2010 Apr;46(6):1012-8. doi: 10.1016/j.ejca.2010.01.010. Epub 2010 Feb 17. Eur J Cancer. 2010. PMID: 20171085
Targeted therapy in head and neck cancer.
Licitra L, Bergamini C, Mirabile A, Granata R. Licitra L, et al. Curr Opin Otolaryngol Head Neck Surg. 2011 Apr;19(2):132-7. doi: 10.1097/MOO.0b013e328344b668. Curr Opin Otolaryngol Head Neck Surg. 2011. PMID: 21372717 Review.
Rare cancers are not so rare: the rare cancer burden in Europe.
Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Gatta G, et al. Among authors: licitra l. Eur J Cancer. 2011 Nov;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25. Eur J Cancer. 2011. PMID: 22033323
447 results